$AVGR
Avinger Inc Stock $avgr

$avgr Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000143774920004451 Filed on March 06, 2020

Income Statement

Concept	2020 Q1	2019	2018 Q4
Revenue	$2.261M	$9.131M	$2.030M
YoY Change	22.88%	15.36%	6.28%
Cost Of Revenue	$1.760M	$6.264M	$1.470M
YoY Change	19.97%	-4.09%	-15.03%
Gross Profit	$501.0K	$2.867M	$560.0K
YoY Change	34.32%	107.15%	211.11%
Gross Profit Margin	22.16%	31.4%	27.59%
Selling, General & Admin	$4.386M	$16.53M	$4.960M
YoY Change	10.04%	-10.16%	5.76%
% of Gross Profit	875.45%	576.7%	885.71%
Research & Development	$1.594M	$5.692M	$1.670M
YoY Change	12.73%	-5.28%	-15.66%
% of Gross Profit	318.16%	198.54%	298.21%
Depreciation & Amortization	$225.0K	$890.0K	$540.0K
YoY Change	12.5%	-30.52%	68.75%
% of Gross Profit	44.91%	31.04%	96.43%
Operating Expenses	$5.980M	$22.23M	$6.630M
YoY Change	10.74%	-8.96%	-0.6%
Operating Profit	-$5.479M	-$19.36M	-$6.070M
YoY Change	8.99%	-15.94%	-6.47%
Interest Expense	$398.0K	$1.480M	-$260.0K
YoY Change	13.71%	-74.0%	-83.33%
% of Operating Profit
Other Income/Expense, Net	-$4.000K	$1.101M	$240.0K
YoY Change	-101.67%	16.02%
Pretax Income	-$5.850M	-$19.45M	-$6.090M
YoY Change	15.61%	-29.43%	-40.0%
Income Tax
% Of Pretax Income
Net Earnings	-$5.851M	-$19.45M	-$6.090M
YoY Change	15.75%	-29.42%	-40.0%
Net Earnings / Revenue	-258.78%	-213.01%	-300.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$400.1K	-$2.686M	-$2.683M
COMMON SHARES
Basic Shares Outstanding	16.81M		23.46M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.860M	$10.94M	$16.41M
YoY Change	-40.99%	-33.33%	204.45%
Cash & Equivalents	$9.862M	$10.94M	$16.41M
Short-Term Investments
Other Short-Term Assets	$1.020M	$310.0K	$640.0K
YoY Change	-56.41%	-51.56%	0.0%
Inventory	$3.875M	$3.910M	$3.422M
Prepaid Expenses
Receivables	$1.352M	$1.460M	$1.154M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$16.11M	$16.62M	$21.62M
YoY Change	-33.18%	-23.13%	88.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.387M	$6.520M	$2.078M
YoY Change	-35.19%	213.46%	-29.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$637.0K	$680.0K
YoY Change
Total Long-Term Assets	$6.687M	$7.210M	$2.078M
YoY Change	212.48%	246.63%	-42.86%
TOTAL ASSETS
Total Short-Term Assets	$16.11M	$16.62M	$21.62M
Total Long-Term Assets	$6.687M	$7.210M	$2.078M
Total Assets	$22.80M	$23.83M	$23.70M
YoY Change	-13.15%	0.55%	57.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.385M	$660.0K	$1.148M
YoY Change	42.93%	-42.61%	-9.82%
Accrued Expenses	$695.0K	$3.160M	$1.449M
YoY Change	-23.29%	19.25%	-59.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.370M	$8.970M	$7.490M
YoY Change	19.52%	19.76%	-83.26%
Total Short-Term Liabilities	$14.46M	$12.79M	$14.20M
YoY Change	11.79%	-9.93%	-71.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$10.00K	$4.140M	$41.00K
YoY Change	-73.68%	10250.0%	-86.38%
Total Long-Term Liabilities	$10.00K	$4.140M	$41.00K
YoY Change	-73.68%	10250.0%	-86.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.46M	$12.79M	$14.20M
Total Long-Term Liabilities	$10.00K	$4.140M	$41.00K
Total Liabilities	$18.39M	$16.93M	$14.24M
YoY Change	41.76%	18.89%	-71.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$354.2M		-$328.9M
YoY Change	6.06%		9.15%
Common Stock	$358.6M		$338.3M
YoY Change	3.28%		27.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.408M	$6.900M	$9.460M
YoY Change
Total Liabilities & Shareholders Equity	$22.80M	$23.83M	$23.70M
YoY Change	-13.15%	0.55%	57.07%

Cashflow Statement

Concept	2020 Q1	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$5.851M	-$19.45M	-$6.090M
YoY Change	15.75%	-29.42%	-40.0%
Depreciation, Depletion And Amortization	$225.0K	$890.0K	$540.0K
YoY Change	12.5%	-30.52%	68.75%
Cash From Operating Activities	-$4.970M	-$17.26M	-$4.030M
YoY Change	-17.11%	-6.51%	-22.2%
INVESTING ACTIVITIES
Capital Expenditures		$88.00K	$380.0K
YoY Change		175.0%
Acquisitions
YoY Change
Other Investing Activities		$20.00K	$0.00
YoY Change		-33.33%
Cash From Investing Activities		-$70.00K	$380.0K
YoY Change		1650.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$3.811M
YoY Change		1113.69%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.889M	11.87M	10.05M
YoY Change	-38.83%	-59.76%	2412.5%
NET CHANGE
Cash From Operating Activities	-4.970M	-17.26M	-4.030M
Cash From Investing Activities		-70.00K	380.0K
Cash From Financing Activities	3.889M	11.87M	10.05M
Net Change In Cash	-1.081M	-5.467M	6.400M
YoY Change	-463.97%	-149.61%	-233.89%
FREE CASH FLOW
Cash From Operating Activities	-$4.970M	-$17.26M	-$4.030M
Capital Expenditures		$88.00K	$380.0K
Free Cash Flow	-$4.970M	-$17.35M	-$4.410M
YoY Change	-18.24%	-6.2%	-14.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018Q1	avgr	Debt Instrument Final Facility Fee Percentage DebtInstrumentFinalFacilityFeePercentage	0.15
CY2015Q3	avgr	Debt Instrument Financing Fee Percentage DebtInstrumentFinancingFeePercentage	0.015
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Next Twelve Months DebtInstrumentCovenantComplianceTargetMinimumRevenueNextTwelveMonths	15000000
CY2019	avgr	Accounts Receivable Allowance For Credit Loss Recovery Writeoff AccountsReceivableAllowanceForCreditLossRecoveryWriteoff	-185000
CY2018	avgr	Accounts Receivable Allowance For Credit Loss Recovery Writeoff AccountsReceivableAllowanceForCreditLossRecoveryWriteoff	-6000
CY2019	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	3580000
CY2018	avgr	Accretion Of Preferred Stock Dividends AccretionOfPreferredStockDividends	2918000
CY2019Q4	avgr	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	101000
CY2018Q4	avgr	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	111000
CY2019Q4	avgr	Accrued Restructuring Charges Current AccruedRestructuringChargesCurrent
CY2018Q4	avgr	Accrued Restructuring Charges Current AccruedRestructuringChargesCurrent	98000
CY2019Q4	avgr	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	89000
CY2018Q4	avgr	Accrued Travel Expenses Current AccruedTravelExpensesCurrent	74000
CY2018	avgr	Change In Deferred Tax Asset Due To New Accounting Principle In Period Of Adoption ChangeInDeferredTaxAssetDueToNewAccountingPrincipleInPeriodOfAdoption	-6000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	5000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum	3500000
CY2015Q3	avgr	Debt Instrument Covenant Compliance Prepayment Multiplier For Revenue Shortfall DebtInstrumentCovenantCompliancePrepaymentMultiplierForRevenueShortfall	2
CY2020Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Next Twelve Months DebtInstrumentCovenantComplianceTargetMinimumRevenueNextTwelveMonths	10000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Second Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear	20000000
CY2020Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Second Year DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear	12000000
CY2018Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Third Year DebtInstrumentCovenantComplianceTargetMinimumRevenueThirdYear	25000000
CY2020Q1	avgr	Debt Instrument Covenant Compliance Target Minimum Revenue Third Year DebtInstrumentCovenantComplianceTargetMinimumRevenueThirdYear	15000000
CY2015Q3	avgr	Debt Instrument Final Facility Fee Percentage DebtInstrumentFinalFacilityFeePercentage	0.15
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16813398
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019Q2	dei	Entity Public Float EntityPublicFloat	19400000
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2015Q3	avgr	Debt Instrument Redemption Initial Prepayment Premium Percentage DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage	0.05
CY2015Q3	avgr	Debt Instrument Redemption Prepayment Premium Percentage After Fifth Year DebtInstrumentRedemptionPrepaymentPremiumPercentageAfterFifthYear	0
CY2019Q4	avgr	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1237000
CY2018Q4	avgr	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability
CY2019Q4	avgr	Deferred Tax Liability Operating Lease Right Of Use Asset DeferredTaxLiabilityOperatingLeaseRightOfUseAsset	1355000
CY2018Q4	avgr	Deferred Tax Liability Operating Lease Right Of Use Asset DeferredTaxLiabilityOperatingLeaseRightOfUseAsset
CY2015Q3	avgr	Debt Instrument Redemption Annual Decline In Prepayment Premium Percentage DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage	0.01
CY2019	avgr	Disposal Of Fully Depreciated Property And Equipment DisposalOfFullyDepreciatedPropertyAndEquipment	54000
CY2018	avgr	Disposal Of Fully Depreciated Property And Equipment DisposalOfFullyDepreciatedPropertyAndEquipment	2849000
CY2019	avgr	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1402000
CY2018	avgr	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability
CY2019	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	1575000
CY2018	avgr	Noncash Interest Expense Income And Other Charges Net NoncashInterestExpenseIncomeAndOtherChargesNet	5634000
CY2019	avgr	Operating Lease Rightofuse Asset Amortization OperatingLeaseRightofuseAssetAmortization	676000
CY2019	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature
CY2018	avgr	Preferred Stock Deemed Dividend Arising From Beneficial Conversion Feature PreferredStockDeemedDividendArisingFromBeneficialConversionFeature	5216000
CY2019	avgr	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts
CY2018	avgr	Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromIssuanceOfConvertiblePreferredStockNetOfIssuanceCosts	15525000
CY2018Q1	avgr	Proceeds From Issuance Or Sale Of Equity Net ProceedsFromIssuanceOrSaleOfEquityNet	15500000
CY2019	avgr	Proceeds From Public Offerings Net Of Issuance Costs ProceedsFromPublicOfferingsNetOfIssuanceCosts
CY2018	avgr	Proceeds From Public Offerings Net Of Issuance Costs ProceedsFromPublicOfferingsNetOfIssuanceCosts	3026000
CY2019	avgr	Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts
CY2018	avgr	Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts	10179000
CY2019	avgr	Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan	63000
CY2018	avgr	Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan	21000
CY2019	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	128000
CY2018	avgr	Product Warranty Accrual Payments And Release ProductWarrantyAccrualPaymentsAndRelease	451000
CY2019	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent	462000
CY2018	avgr	Reclassification Of Right Of Use Asset To Prepaid Rent ReclassificationOfRightOfUseAssetToPrepaidRent
CY2018	avgr	Stock Issued During Period Value Purchase Agreement StockIssuedDuringPeriodValuePurchaseAgreement	314000
CY2018	avgr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	581000
CY2019	avgr	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	7993000
CY2019	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment	408000
CY2018	avgr	Transfer Between Inventories And Property And Equipment TransferBetweenInventoriesAndPropertyAndEquipment	51000
CY2019	avgr	Warranty Period WarrantyPeriod	P1Y
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001506928
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019	dei	Entity Registrant Name EntityRegistrantName	Avinger Inc
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2019	dei	Trading Symbol TradingSymbol	avgr
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	663000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1148000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1458000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1154000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	654000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1449000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	30000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	41000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3948000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3155000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	355220000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	338342000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	2918000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	3580000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3080000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2091000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2091000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3080000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	260000
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	146000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	19000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	19000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	260000
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	171000
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	117000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3721024
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2218693
CY2019Q4	us-gaap	Assets Assets	23825000
CY2018Q4	us-gaap	Assets Assets	23699000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	16624000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	21621000
CY2019Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2018Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10943000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16410000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5389000
CY2019	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5467000
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11021000
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1797900
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2753999
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4757539
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10364663
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3492200
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10364663
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3492200
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	10000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	6264000
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	6531000
CY2019	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1
CY2018	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	42794000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1553000
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	176000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	84308000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	78258000
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1553000
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	176000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	75863000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	70286000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4361000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3655000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2847000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4317000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	82755000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78082000
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	198000
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	176000
CY2019	us-gaap	Depreciation Depreciation	890000
CY2018	us-gaap	Depreciation Depreciation	934000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	890000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1281000
CY2019Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent
CY2018Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	2918000
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.18
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-33.42
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1782000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1197000
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2018	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	11000
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-13000
CY2019	us-gaap	Gross Profit GrossProfit	2867000
CY2018	us-gaap	Gross Profit GrossProfit	1384000
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5787000
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2102000
CY2019Q4	us-gaap	Inventory Net InventoryNet	3912000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	97000
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	228000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-4000
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1022000
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1023000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	192000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5205000
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6582000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4084000
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-485000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-125000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	248000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	160000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-795000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2208000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	585000
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	334000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1169000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	92000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-658000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-340000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-34000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-260000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-128000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5000
CY2019	us-gaap	Interest Expense InterestExpense	1480000
CY2018	us-gaap	Interest Expense InterestExpense	5692000
CY2019	us-gaap	Interest Paid Net InterestPaidNet
CY2018	us-gaap	Interest Paid Net InterestPaidNet	60000
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1890000
CY2018Q4	us-gaap	Inventory Net InventoryNet	3422000
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1426000
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1162000
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	596000
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	158000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	272000
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	914000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	288000
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	214000
CY2019	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims
CY2018	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	106000
CY2019Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.065
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5800000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5711000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1085000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1138000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1203000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1162000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1123000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	854000
CY2019Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2019Q4	us-gaap	Liabilities Liabilities	16930000
CY2018Q4	us-gaap	Liabilities Liabilities	14239000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23825000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23699000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12788000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14198000
CY2015Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	50000000
CY2019	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Organization</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">Organization, Nature of Business</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2007.</div> The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “OCT”) </div>visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, Lightbox, as well as a variety of disposable catheter products. The Company’s current products include its non-imaging catheters, Wildcat and Kittycat, as well as its Lumivascular platform products, Ocelot, Ocelot PIXL and Ocelot MVRX, all of which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) clearance from the U.S. Food and Drug Administration (“FDA”) for commercialization of Pantheris, the Company’s image-guided atherectomy system, designed to allow physicians to precisely remove arterial plaque in PAD patients. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2018, </div>the Company also received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">510</div>(k) clearance from the FDA for its next-generation of Pantheris. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2019, </div>the Company further received FDA clearance for Pantheris SV, a lower profile Pantheris, and commenced sales in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2019. </div>The Company has sales in the U.S. and select international markets. The Company is located in Redwood City, California.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">Liquidity Matters</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic;">Presentation of Financial Statements - Going Concern (Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">205</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div>) </div>requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year from the date of the issuance of these financial statements.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019, </div>the Company had an accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$348.3</div> million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.9</div> million at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and expected revenues and funds from operations will be sufficient to allow the Company to fund its current operations through at least the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div> Even though we received net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.7</div> million from the sale of our common stock in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2020 </div>offering, net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.8</div> million from the sales of our common stock in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2019 </div>offering, proceeds from issuance of common stock upon the exercise of warrants during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May </div>of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.0</div> million, net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.2</div> million from the sale of our Series C preferred stock and common stock in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2018 </div>offering, net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million from the sale of common stock and warrants in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2018 </div>offering, and net proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.5</div> million from the sale of our Series B preferred stock and warrants in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018 </div>offering, the Company will need to raise additional funds through future equity or debt financings within the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months to meet its operational needs and capital requirements for product development, clinical trials and commercialization and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>subsequently require additional fundraising.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company can provide <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> create substantial dilution for our existing stockholders. Given the recent decline in the Company’s stock price, any financing that we undertake in the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months could cause substantial dilution to our existing stockholders, there can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>have to significantly reduce its operations or delay, scale back or discontinue the development of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more of its products. The financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div style="text-align: center; width: 100%"> <div> <div style="text-align: center; font-size: 10pt; font-family: Times New Roman;"> </div></div></div></div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”), the entire amount of borrowings at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> has been classified as current in these financial statements. CRG has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> invoked the material adverse change clause.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Public Offerings</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,979</div> shares of Series B preferred stock and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,797,900</div> shares of common stock. As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.5</div> million after underwriting discounts, commissions, legal and accounting fees. The Series B preferred stock has a liquidation preference of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share, full ratchet price based anti-dilution protection, has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights and is subject to certain ownership limitations. The Series B preferred stock is immediately convertible at the option of the holder, has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> stated maturity, and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> pay regularly stated dividends or interest. Each share of Series B preferred stock is accompanied by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Series <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> warrant that expires on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seventh</div> anniversary of the date of issuance to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div> shares of common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Series <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> warrant that expires on the earlier of (i) the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seventh</div> anniversary of the date of issuance or (ii) the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60th</div> calendar day following the receipt and announcement of FDA clearance of our Pantheris below-the-knee device (or the same or similar product with a different name) to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div> shares of common stock; provided, however, if at any time during such <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div>-day period the volume weighted average price for any trading day is less than the then effective exercise price, the termination date shall be extended to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> year anniversary of the initial exercise date. FDA clearance of Pantheris SV was received in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2019, </div>triggering this <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div>-day period. During the entire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div>-day period following clearance, the volume weighted average price was less than the then effective exercise price. As such, all Series <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> warrants are currently deemed to expire on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seventh</div> anniversary of the date of issuance. In addition, pursuant to the Series A Purchase Agreement, we issued to CRG <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,800</div> shares of Series A preferred stock at the closing of the Series B Offering. The Series A preferred stock was issued in exchange for the conversion of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$38.0</div> million of the outstanding principal amount of their senior secured term loan (plus the back-end fee and prepayment premium applicable thereto), totaling approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$41.8</div> million. The Series A preferred stock is initially convertible into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,090,000</div> shares of common stock subject to certain limitations contained in the Series A Purchase Agreement.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we entered into a securities purchase agreement with certain investors pursuant to which we agreed to sell and issue, in a registered direct offering, an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216,618</div> shares of our common stock at an offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16.425</div> per share. In a concurrent private placement, or the Private Placement, we agreed to issue to these investors warrants exercisable for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of our common stock for each <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> shares purchased in the registered direct offering, which equals an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">108,309</div> shares of common stock. The closing of such registered direct offering and the concurrent Private Placement occurred on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> in connection with which we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million after deducting placement agent fees and other expenses payable by us. The warrants have an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.80</div> per share of our common stock and expire on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2021.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 1, 2018, </div>we completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">728,500</div> shares of common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,586</div> shares of Series C convertible preferred stock (the “Series C preferred stock”). As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.2</div> million after underwriting discounts, commissions, legal and accounting fees. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series C preferred stock will be entitled to receive distributions out of our assets, whether capital or surplus, of an amount equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share of Series C preferred stock before any distributions shall be made on the common stock but after distributions shall be made on any outstanding Series A preferred stock and any of our existing or future indebtedness. The Series C preferred stock has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> voting rights.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 26, 2019, </div>we completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,813,559</div> shares of common stock at an offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.18</div> per share. As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.8</div> million after underwriting discounts, commissions, legal and accounting fees and the conversion price of the outstanding shares of Series B preferred stock, issued in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018 </div>offering, was reduced to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.18</div> per share as a result. </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 31, 2020, </div>we completed a public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,428,572</div> shares of common stock at an offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.70</div> per share. As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.7</div> million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Due to anti-dilution provisions, the conversion price of the outstanding shares of Series B preferred stock, which was issued in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018 </div>offering, was reduced to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.70</div> per share.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style="width: 100%; margin-left: 0pt; margin-right: 0pt"> <div style="text-align: center; width: 100%"> <div> <div style="text-align: center; font-size: 10pt; font-family: Times New Roman;"> </div></div></div></div></div>
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11867000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29491000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17264000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18466000
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	45671
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	311000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	635000
CY2019	us-gaap	Operating Expenses OperatingExpenses	22226000
CY2018	us-gaap	Operating Expenses OperatingExpenses	24413000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-19359000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19450000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-27558000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23030000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-35692000
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-23029000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	1400000
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	2000000
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	6000000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4857000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	722000
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4135000
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6000000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4856000
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	202000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	418000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	684000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	41000
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	51000
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-126000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1101000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	949000
CY2019	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts
CY2018	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	155000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	88000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32000
CY2019	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3580000
CY2018	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2918000
CY2019Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	48325000
CY2018Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	44718000
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	48503
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	45671
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	48503
CY2019Q4	us-gaap	Prepaid Rent PrepaidRent	461000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3811000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	314000
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	18000
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	28000
CY2019Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8000000
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7993000
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	581000
CY2018Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	272000
CY2017Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	390000
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	215000
CY2019Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	214000
CY2018Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	272000
CY2019	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	71000
CY2018	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	333000
CY2019	us-gaap	Profit Loss ProfitLoss	-19450000
CY2018	us-gaap	Profit Loss ProfitLoss	-27558000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5609000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5227000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1661000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2078000
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-56000
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	120000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5692000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6009000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-348335000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-328885000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9131000
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7915000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4680000
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2019Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	18000
CY2018Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	435000
CY2019Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	8967000
CY2018Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	7486000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16534000
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18404000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	2091000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	3080000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7224000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1310.25
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2550000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	448000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	259000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	105000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3100000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7663000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7954000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7401000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2917.30
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1707.30
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1309.47
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7401000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1309.47
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2725.80
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3061.09
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3493.70
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1929.52
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.70
CY2019Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	7224
CY2019Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	7401
CY2019Q4	us-gaap	Share Price SharePrice	1.14
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y292D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y295D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y295D
CY2019Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	1310.25
CY2019Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1309.47
CY2019	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y295D
CY2019	us-gaap	Stock Issued1 StockIssued1	6498000
CY2018	us-gaap	Stock Issued1 StockIssued1
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	21000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	72000
CY2018	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	106000
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross
CY2019	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	6498000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-35690000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	9460000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	6895000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1760000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1747000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2094000
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	16000
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	177000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	29000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	157000
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, the valuation of compound embedded derivatives, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>undertake in the future, actual results <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>ultimately materially differ from these estimates and assumptions.</div></div></div>
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4700000
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7600000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7239000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1068000
CY2019	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0
CY2018	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0

Files In Submission

Name	View Source	Status
0001437749-20-004451-index-headers.html	Edgar Link	pending
0001437749-20-004451-index.html	Edgar Link	pending
0001437749-20-004451.txt	Edgar Link	pending
0001437749-20-004451-xbrl.zip	Edgar Link	pending
avgr-20191231.xml	Edgar Link	completed
avgr-20191231.xsd	Edgar Link	pending
avgr-20191231_cal.xml	Edgar Link	unprocessable
avgr-20191231_def.xml	Edgar Link	unprocessable
avgr-20191231_lab.xml	Edgar Link	unprocessable
avgr-20191231_pre.xml	Edgar Link	unprocessable
avgr20191231_10k.htm	Edgar Link	pending
ex_174903.htm	Edgar Link	pending
ex_174904.htm	Edgar Link	pending
ex_174905.htm	Edgar Link	pending
ex_174906.htm	Edgar Link	pending
ex_175484.htm	Edgar Link	pending
ex_175486.htm	Edgar Link	pending
ex_175488.htm	Edgar Link	pending
ex_175489.htm	Edgar Link	pending
ex_175490.htm	Edgar Link	pending
ex_175774.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVGR
Avinger Inc Stock $avgr

2020 Q1 Form 10-K Financial Statement

#000143774920004451 Filed on March 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR Avinger Inc Stock $avgr

2020 Q1 Form 10-K Financial Statement

#000143774920004451 Filed on March 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVGR
Avinger Inc Stock $avgr